Blood transcript analysis and metastatic recurrent small bowel carcinoid management

Irvin M. Modlin, Ignat Drozdov, Lisa Bodei, Mark Kidd

Research output: Contribution to journalArticlepeer-review


Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and 68Ga-DOTA-PET/CT in a patient with NET.Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.

Original languageEnglish
Article number564
JournalBMC Cancer
Issue number1
Publication statusPublished - Aug 5 2014


  • Gallium
  • Biomarker
  • Blood
  • Carcinoid
  • Chromogranin A
  • Gene marker
  • Neuroendocrine tumor
  • PCR
  • PET/CT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics
  • Medicine(all)


Dive into the research topics of 'Blood transcript analysis and metastatic recurrent small bowel carcinoid management'. Together they form a unique fingerprint.

Cite this